Bio-Rad Laboratories, Inc. (BIO) Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 226.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,488 shares of the medical research company’s stock after acquiring an additional 30,179 shares during the period. Prudential Financial Inc. owned about 0.15% of Bio-Rad Laboratories worth $9,841,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. World Asset Management Inc raised its holdings in shares of Bio-Rad Laboratories by 1.4% during the second quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after acquiring an additional 14 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Bio-Rad Laboratories by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after acquiring an additional 29 shares during the period. US Bancorp DE raised its holdings in shares of Bio-Rad Laboratories by 0.8% during the second quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock worth $956,000 after acquiring an additional 34 shares during the period. State of Wisconsin Investment Board raised its holdings in shares of Bio-Rad Laboratories by 1.0% during the second quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after acquiring an additional 40 shares during the period. Finally, Great West Life Assurance Co. Can raised its holdings in shares of Bio-Rad Laboratories by 0.5% during the second quarter. Great West Life Assurance Co. Can now owns 12,447 shares of the medical research company’s stock worth $2,816,000 after acquiring an additional 67 shares during the period. Institutional investors and hedge funds own 62.85% of the company’s stock.

A number of brokerages recently commented on BIO. BidaskClub upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 5th. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. TheStreet lowered shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $228.80.

TRADEMARK VIOLATION NOTICE: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/13/bio-rad-laboratories-inc-bio-shares-bought-by-prudential-financial-inc.html.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 218.04 on Wednesday. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 430.91 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 52 week low of $154.89 and a 52 week high of $242.79. The firm has a 50-day moving average of $222.70 and a 200 day moving average of $216.60.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 28.29% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply